Differential protection induced by immunization with variable doses of a Leishmania antigenic extract against Leishmania amazonensis. by COELHO, V. T. S. et al.
Cadernos Técnicos de Saúde, no 06 - Abril de 2019
8
DIFFERENTIAL PROTECTION INDUCED BY 
IMMUNIZATION WITH VARIABLE DOSES 
OF A LEISHMANIA ANTIGENIC EXTRACT 
AGAINST LEISHMANIA AMAZONENSIS
Coelho, V.T.S.¹,4; Chávez-Fumagalli,M.A.1; Rodrigues, F.M.4; 
Oliveira, D.M.2; Silva, J.A.O 1,5 ; Costa, L.E.1,4 ; Mendonça, 
D.V.C.1;  Araujo, M.N.1.5; Foureaux, E.C.M.1; Martins, V.T.1; 
Figueiredo, J.E.F.6; Coelho, E.A.F.1¹.
Contato: 
E-mail: viniciotadeu@yahoo.com.br
Experimental vaccines have been developed to protect against leishmaniasis using the 
still does not exist. To determine factors inherent to immunogens that might abrogate 
vaccine immunogen able to induce the best level of protection in BALB/c mice against 
of SLA in BALB/c mice can bring about the development of a protective immune res-
soluble Leishmania antigenic extracts.
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INTRODUCTION 
the intracellular protozoan parasite Leishmania
-
ing on the parasite species and the immunological sta-
-
Among the Leishmania species reported as sources 
-
sidered an important etiological agent of leishmani-
asis due to presents a wide spectrum of clinical dis-
have been developed to induce protection against 
major has been associated with the development of a 
L. amazonensis
a Th1 predominant response is reported as a resistant 
It has been demonstrated that an important challenge 
immune response in the protected animals.
Since the concentration used of an immunogen 
Leishmania antigenic 
to determine the best dose of this vaccine immunogen 
able to induce the best level of protection in BALB/c 
mice against L. amazonensis infection.
2. MATERIALS AND METHODS
from the Biological Sciences Institute from the Federal 
the experimental protocols.
Soluble Leishmania amazonensis antigenic ex-
-
-
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sub
-
promastigotes of L. amazonensis were injected in the 
-
the infected hind foot compared to the uninfected left 
-
-
and homogenized using a glass tissue grinder in sterile 
-
-
with a 10-1 to 10-10 dilution. Each sample was plated 
-
one well to another. Results are expressed as the nega-
2.6. Cytokine production
were 
suspensions were collected of mice immunized and/or 
-
-
Leishmania -
performed to determine the best SLA concentration and 
-
-
-
P<0.01. The 
3. RESULTS
Since the activation of a Th1 immune response 
important requirement for protection against the 
-
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month after the last vaccine dose  and before chal-
lenge infection.
-
-
cultures from the control groups (saline and alum 
-
cultures of the mice immunized with SLA or SLA/
higher in animals that did not receive alum as ad-
juvant when compared to those immunized with 
the groups was observed.
Figure 1. Cellular response elicited in BALB/c mice immunized with variable doses of SLA 
with or without alum. Spleen cells obtained from mice one month after the last vaccine dose were 
cultured in vitro and unstimulated (DMEM medium; background control) or stimulated with SLA 
-
sessed by capture ELISA in the culture supernatants. Each bar represents the mean ± standard de-
viation (SD) of data from four individual mice per group. Differences were considered statistically 
significants between animals immunized with 1, 50 or 100 µg of SLA with (SLA/alum) or without 
(SLA) alum and control groups (A: P<0.005); between mice immunized with 1, 50 or 100 µg of SLA 
in comparison to SLA/alum groups (B: P<0.005), and between mice immunized with 50 or 100 µg 
of SLA in comparison to SLA/alum groups (C: P<0.005). Data shown are representative of three 
independent experiments with similar results.
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-
proportional to the size of the received immunogen 
-
-
mals that received alum as adjuvant when compared 
to the mice that had not been inoculated with this 
-
mune response mounted before challenge infec-
-
or SLA/alum primed the animals for the devel-
mice immunized with a low dose of immunogen 
The protective effect of the immunization using 
Figure 2. Antibodies´ production in BALB/c mice immunized with variable doses of SLA with or 
without alum. Sera samples obtained from mice one month after the last vaccine dose were tested by 
represents the mean ± standard deviation (SD) of data from four individual mice per group. Sera were 
tested by ELISA to determine the presence of IgE and IgG (Panel A) antibodies, and IgG1 and IgG2a 
1, 50 or 100 µg of SLA with (SLA/alum) or without (SLA) alum and control groups (A: P<0.005), 
and between mice immunized with 1, 50 or 100 µg of SLA in comparison to SLA/alum groups (B: 
P<0.005). Data shown are representative of three independent experiments with similar results.
-
-
-
parasite load in the animals immunized with 1 µg 
-
-
and in the parasite load in the infected footpads 
of alum into the immunogens presented the worst 
results of protection in comparison to animals that 
not received this adjuvant.
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we detected that the profile of immune response 
spleen cells cultures of these animals produced 
comparison to animals immunized with 1 µg and 
Figure 3. Leishmania amazonensis protection assays. BALB/c mice (n=8 per group) were immu-
alum in their left hind footpad. One month after, mice (n=4 per group) were infected with 106 station-
ary-phase promastigotes of L. amazonensis into their right hind footpad. Control mice received ster-
ile PBS with or without alum. Panel A shows the lesion development (footpad swelling) in the infected 
mice, monitored weekly with a calliper. Panel B shows the parasite load detected in the infected foot-
pads, 8 weeks after challenge. Number of viable parasites was determined by a limiting dilution assay 
as described in the Material and Methods Section. Mean  standard deviation (SD) of each group is 
or 100 µg of SLA with (SLA/alum) or without (SLA) alum and control groups (A: P<0.005); between 
mice immunized with 1, 50 or 100 µg of SLA in comparison to SLA/alum groups (B: P<0.005); and 
between mice immunized with 50 or 100 µg of SLA in comparison to SLA/alum groups (C: P<0.005). 
Data shown are representative of three independent experiments with similar results.
of the immunogenic preparation. The SLA-driven 
-
of SLA or SLA/alum showed a lower production 
-
L. amazonensis challenge infection.   
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Figure 4. Cytokines´ production by spleen cells of BALB/c mice infected with L. amazonensis. 
Spleen cells suspensions were obtained from immunized and infected mice, 8 weeks after L. amazo-
nensis challenge infection. Cells were unstimulated (DMEM medium; background control) or stimu-
-
(SLA/alum) or without (SLA) alum and control groups (A: P<0.005); between mice immunized with 1, 
50 or 100 µg of SLA in comparison to SLA/alum groups (B: P<0.005), and between mice immunized 
with 50 or 100 µg of SLA in comparison to SLA/alum groups (C=P<0.005). Data shown are repre-
sentative of three independent experiments with similar results.
-
tibodies after infection in the animals immunized with 
SLA or SLA/alum were lower in comparison to con-
induce a higher production of antibodies in the immu-
-
-
-
lenge infection.
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Figure 5. Antibodies´ production after L. amazonensis challenge infection. Mice were immunized 
and challenged with L. amazonensis and eight weeks after sera samples were collected. Sera were 
and IgG1 and IgG2a (Panel B) isotypes. Each bar represents the mean ± standard deviation (SD) 
between mice immunized with 1, 50 or 100 µg of SLA with (SLA/alum) or without (SLA) alum and 
control groups (A: P<0.005), and between mice immunized with 1, 50 or 100 µg of SLA in comparison 
to SLA/alum groups (B: P<0.005). Data shown are representative of three independent experiments 
with similar results.
4. DISCUSSION
Experimental vaccines have been tested to pro-
tect against Leishmania
to induce an effective protection against disease. 
-
sidered a reasonable alternative due to their immu-
-
-
against L. amazonensis infection.
dose is critical in determining the direction in which 
100 µg of SLA. 
-
-
-
-
Leishmania 
-
L. amazonensis 
-
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tal role to induce protection in BALB/c mice vacci-
nated with L. infantum ribosomal proteins against L. 
amazonensis or L. chagasi
-
 L. amazo-
nensis
protected animals.
-
-
-
-
-
showed that BALB/c mice immunized with a plasmid 
L. amazonensis or L. donovani
of BALB/c mice to L. amazonensis 
The evaluation of humoral response in the immu-
nized and protected mice demonstrates that the pro-
duction of Leishmania
-
tion against L. amazonensis -
presented a rapid evolution of the infection and disea-
-
vels after challenge infection in the protected animals.
a critical role in the pathogenesis of L. amazonensis
-
gens to T cells have suggested that internalization via 
-
Leishmania
macrophages. These facts corroborate with the idea of 
also how much of immunogens should be administered 
to protect against Leishmania -
-
-
mice can bring about the development of a protective 
-
candidate appears to be fundamental to determining the 
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